5DG Stock Overview Operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Ocumension Therapeutics Competitors Price History & Performance
Summary of share price highs, lows and changes for Ocumension Therapeutics Historical stock prices Current Share Price HK$0.52 52 Week High HK$0.86 52 Week Low HK$0.47 Beta 0.80 1 Month Change -17.60% 3 Month Change -16.94% 1 Year Change -30.87% 3 Year Change -72.61% 5 Year Change n/a Change since IPO -86.29%
Recent News & Updates
Ocumension Therapeutics Announces Patient Enrollment Completed in the Second Phase III Clinical Trial of OT-301 in China Dec 03
Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director Oct 21
New minor risk - Shareholder dilution Oct 20
Ocumension Therapeutics Announces New Drug Application of OT-502 Accepted by the National Medical Products Administration Sep 24
Ocumension Therapeutics Announces New Drug Application of OT-1001 Approved by the National Medical Products Administration Sep 19
New minor risk - Profitability Aug 15 See more updates
Ocumension Therapeutics Announces Patient Enrollment Completed in the Second Phase III Clinical Trial of OT-301 in China Dec 03
Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director Oct 21
New minor risk - Shareholder dilution Oct 20
Ocumension Therapeutics Announces New Drug Application of OT-502 Accepted by the National Medical Products Administration Sep 24
Ocumension Therapeutics Announces New Drug Application of OT-1001 Approved by the National Medical Products Administration Sep 19
New minor risk - Profitability Aug 15
First half 2024 earnings released: CN¥0.23 loss per share (vs CN¥0.32 loss in 1H 2023) Aug 14
Now 21% undervalued after recent price drop Aug 05
Ocumension Therapeutics to Report First Half, 2024 Results on Aug 12, 2024 Jul 30
Ocumension Therapeutics Announces Biologic License Application for OT-702 Accepted by the National Medical Products Administration Jul 17
Ocumension Therapeutics, Annual General Meeting, Jun 20, 2024 May 25
Full year 2023 earnings released: CN¥0.58 loss per share (vs CN¥0.64 loss in FY 2022) Apr 30
Now 21% undervalued after recent price drop Mar 27
Full year 2023 earnings released: CN¥0.59 loss per share (vs CN¥0.64 loss in FY 2022) Mar 24
Forecast to breakeven in 2025 Mar 24
New major risk - Revenue and earnings growth Mar 23
Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202 Mar 14
Ocumension Therapeutics to Report Fiscal Year 2023 Results on Mar 21, 2024 Mar 08 Ocumension Therapeutics (SEHK:1477) commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023. Dec 14
Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China Nov 30
Ocumension Therapeutics Completes Patient Enrollment in the Phase II Clinical Trial of OT-202 in China Nov 23
Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023 Oct 01
New minor risk - Profitability Aug 28
First half 2023 earnings released: CN¥0.32 loss per share (vs CN¥0.31 loss in 1H 2022) Aug 27
Ocumension Therapeutics to Report First Half, 2023 Results on Aug 24, 2023 Aug 15
Ocumension Therapeutics Announces Clinical Trial Authorization for Initiating A Phase III Clinical Trial of Ot-101-S Jul 23
Forecast to breakeven in 2025 Jul 07
Ocumension Therapeutics Completes Patient Enrollment in Globalmulti-Center Phase III Clinical Trial of OT-101 Jun 02
Full year 2022 earnings released: CN¥0.64 loss per share (vs CN¥0.43 loss in FY 2021) Mar 31
Ocumension Therapeutics Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended December 31, 2022 Feb 15
Forecast to breakeven in 2024 Feb 06
Ocumension Therapeutics Provides Update on Phase I Clinical Trial of Ot-202 Feb 04
Ocumension Therapeutics Announces Patient Enrollment Complete in the Phase III Clinical Trial of OT-101 in China Feb 02
Now 21% undervalued after recent price drop Jan 11
Less than half of directors are independent Nov 16
First half 2022 earnings released: CN¥0.31 loss per share (vs CN¥0.12 loss in 1H 2021) Aug 28
Ocumension Therapeutics to Report First Half, 2022 Results on Aug 26, 2022 Aug 17
Ocumension Therapeutics Receives Approval from the National Medical Products Administration for Yutio Chronic Non-Infectious Uveitis Jun 24
EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ(R) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye Jun 22
Ocumension Therapeutics Announces Executive Changes Jun 16
Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-703 in China Jun 10
Ocumension Therapeutics Receives Approval from the National Medical Products Administration for its IND Application to Begin the Phase Iii Clinical Study for Fluocinolone Acetonide Intravitreal Implant Jun 09
Less than half of directors are independent Apr 27
Ocumension Therapeutics Appoints Mr. Zhenyu Zhang as Independent Non-Executive Director, the Chairman of the Remuneration Committee and a Member of the Nomination Committee and Audit Committee Apr 09
Ocumension Therapeutics Announces Demise of Lianming HE, Independent Non-Executive Director, Chairman of the Remuneration Committee and Member of the Audit Committee and Nomination Committee Apr 01
Forecast to breakeven in 2024 Mar 30
Ocumension Therapeutics Voluntary Announcement primary Clinical Endpoint Achieved in the Phase III clinical Trial of OT-1001 Mar 04
Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China Mar 03
Ocumension Therapeutics Announces First Patient Enrolled in the Clinical Trial of self-Developed Class I New Drug OT-202 in China Jan 05
First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020) Sep 24
Ocumension Therapeutics Receives CDE Approval for Commencement of a Phase III Clinical Trial OT-502 (DEXYCU®) in China Sep 15
First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020) Aug 23
Ocumension Therapeutics MHRA Approval Received for Phase III Clinical Trial of OT-101 in the United Kingdom Aug 04
Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-101 Jul 15
Ocumension Therapeutics Announces Clinical Trial Authorization for Initiatinga Phase III Clinical Trial of OT-101 Accepted in United Kingdom May 21
Ocumension Therapeutics Announces Investigational New Drug Application for Initiating A Multi-Regional Phase Iii Clinical Trial in the People's Republic of China for OT-101 May 12
Non-Executive Director has left the company Mar 24
Ocumension Therapeutics Announces Board Changes Mar 21
Ocumension Therapeutics, Annual General Meeting, Jun 29, 2021 Mar 20
New 90-day low: €2.32 Mar 12
Ocumension Therapeutics to Report Fiscal Year 2020 Results on Mar 19, 2021 Mar 10
Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Denali Phase 3 Trial Mar 05
Ocumension Therapeutics Announces Second Phase III Clinical Trial of OT-301 Approved in China Mar 04
Ocumension Therapeutics Announces Investigational New Drug Approval for Initiating A Multi-Regional Phase III Clinical Trial Feb 23
Ocumension Therapeutics Announces Phase III Clinical Trial of the Recently In-Licensed Drug Candidate of the Group Feb 10
Ocumension Therapeutics has completed a Follow-on Equity Offering in the amount of HKD 1.5876 billion. Jan 24
Ocumension Therapeutics announced that it expects to receive HKD 793.8 million in funding from 6 Dimensions Capital, L.P. Jan 14
New 90-day high: €3.00 Jan 12 Ocumension Therapeutics Announces First Patient Enrolled in the Phase III Clinical Trial of OT-1001 (Zerviate) in China
New 90-day high: €2.70 Dec 22
Ocumension Therapeutics Initiates the Real World Study of Its Core Product, OT-401 (YUTIQ) in Boao Super Hospital in Hainan Province, China Dec 02
Ocumension Therapeutics Receives Approval by Chinese Authorities for Local Start of Mont Blanc Phase 3 Trial Oct 27
New 90-day low: €2.30 Oct 24
Ocumension Therapeutics Receives Approval from China’S Center for Drug Evaluation of the National Medical Products Administration Sep 22
Ocumension Therapeutics to Report First Half, 2020 Results on Aug 26, 2020 Aug 18
Ocumension Therapeutics announced that it has received $20 million in funding Jul 17 Shareholder Returns 5DG DE Pharmaceuticals DE Market 7D -4.6% -0.3% -0.3% 1Y -30.9% -17.0% 7.0%
See full shareholder returns
Return vs Market: 5DG underperformed the German Market which returned 6.8% over the past year.
Price Volatility Is 5DG's price volatile compared to industry and market? 5DG volatility 5DG Average Weekly Movement 9.9% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 5DG's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5DG's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, blepharitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, acute glaucoma, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis.
Show more Ocumension Therapeutics Fundamentals Summary How do Ocumension Therapeutics's earnings and revenue compare to its market cap? 5DG fundamental statistics Market cap €445.58m Earnings (TTM ) -€42.49m Revenue (TTM ) €40.85m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 5DG income statement (TTM ) Revenue CN¥310.29m Cost of Revenue CN¥129.44m Gross Profit CN¥180.86m Other Expenses CN¥503.58m Earnings -CN¥322.73m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.40 Gross Margin 58.29% Net Profit Margin -104.01% Debt/Equity Ratio 0%
How did 5DG perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 17:37 End of Day Share Price 2024/12/23 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Ocumension Therapeutics is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Yanyin Zhu China International Capital Corporation Limited Fang Quan China International Capital Corporation Limited Ziyi Chen Goldman Sachs
Show 3 more analysts 
